Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,223 across all filing types
Latest filing 2014-06-19 Board/Management Inform…
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
Other Report or Announcement
Board/Management Information Classification · 100% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, XTL Biopharmaceuticals Ltd., dated June 18, 2014. It reports changes in director positions on the board, specifically naming a new chairman and changes in committee membership. The document is relatively short (3664 characters) and focuses on management/board changes rather than financial results or detailed reports. There is no financial data or comprehensive report content, only an announcement of board changes. Therefore, it fits the category of Board/Management Information (MANG).
2014-06-19 Hebrew (modern)
Other Report or Announcement
Report Publication Announcement Classification · 98% confidence The document is very short (1752 characters) and explicitly states that an attached report concerns 'Changes in audit committee and compliance with NASDAQ requirements.' It references an attached PDF file (*6-19-14-XTL_isa.pdf*) and is filed under 'Other Report or Announcement' concerning regulations for a foreign corporation. This structure—an announcement stating that a specific report is attached or published—fits the definition of a Report Publication Announcement (RPA) according to Rule 2 ('MENU VS MEAL' rule). While the content relates to governance/compliance, the document itself is the notification of publication, not the detailed report.
2014-06-19 English
FORM 6-K
Regulatory Filings
2014-06-18 English
Other Report or Announcement
Regulatory Filings Classification · 95% confidence The document is a press release announcing that XTL Biopharmaceuticals received correspondence from Nasdaq regarding noncompliance with audit committee requirements due to a director's resignation. It discusses the Nasdaq listing rule 5605 and the company's plan to remedy the deficiency within the cure period. There are no financial statements, detailed financial data, or comprehensive report content. The document is an announcement about regulatory compliance related to listing requirements, not an audit report, annual report, or other financial filing. It is also not a certification letter or a voting result announcement. Given the nature of the content as a regulatory compliance update and the absence of detailed financial or management report data, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements that do not fit other categories. The document length is short (3313 characters), consistent with an announcement rather than a full report.
2014-06-12 Hebrew (modern)
Other Report or Announcement
Regulatory Filings Classification · 95% confidence The document is very short (1686 characters) and explicitly states that it is an 'Other Report or Announcement' and that it is 'Attached hereto is a report on *NASDAQ letter regarding noncompliance with audit committee requirements.*'. This structure—a brief announcement pointing to an attached document concerning a specific regulatory or compliance issue (NASDAQ noncompliance)—fits the definition of a general regulatory announcement that doesn't fit a more specific category like 10-K, ER, or IR. Since it is an announcement about a specific regulatory matter (a NASDAQ letter) and acts as a general disclosure mechanism, the most appropriate classification is Regulatory Filings (RNS), as it is a miscellaneous regulatory disclosure that doesn't map directly to the other specific types (like DIRS, DIV, or LTR, although it relates to compliance). Given the 'MENU VS MEAL' rule, it is an announcement of a report/letter, not the report itself. RNS is the best fit for general regulatory disclosures not covered elsewhere.
2014-06-12 English
Immediate Report
Interim / Quarterly Report Classification · 95% confidence The document is a detailed financial and operational results announcement for the first quarter of 2014, including comprehensive financial data such as consolidated statements of financial position and comprehensive income. It covers the quarter ended March 31, 2014, which is a period shorter than a full fiscal year, indicating it is an interim or quarterly report. The presence of actual financial statements and substantive financial data confirms it is not merely an announcement or summary. There is no indication that this is a full annual report (10-K) or just an earnings release (ER) with key highlights only. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2014
2014-06-02 Hebrew (modern)

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.